917969-48-3

Upstream product

• 1679-18-1 4-Chlorophenylboronic acid 
• 917969-40-5 3-bromo-2-chloro-4-(4-chlorophenyl)pyridine 
• 884494-53-5 3-bromo-2-chloro-4-iodopyridine 
• 52200-48-3 3-bromo-2-chloropyridine 
• 917969-47-2 2-chloro-4-(4-chlorophenyl)-3,4'-bipyridine 

Downstream Products

• 917969-49-4 7-(4-chlorophenyl)-8-(pyridin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 
• 917969-50-7 3-((7-(4-chlorophenyl)-3-oxo-8-(pyridin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)methyl)-6-(trifluoromethyl)picolinoyl chloride 
• 917968-80-0 2-((2-chloro-6-(trifluoromethyl)pyridin-3-yl)methyl)-7-(4-chlorophenyl)-8-(pyridin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 
• 917968-89-9 3-((7-(4-chlorophenyl)-3-oxo-8-(pyridin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)methyl)-2-methyl-6-(trifluoromethyl)pyridine 1-oxide 

Relevant academic research and scientific papers

Triazolopyridine cannabinoid receptor 1 antagonists

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.